NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription

References

• Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26(2):153–17. doi:10.1055/s-2006-939753.
   PubMed Web of Science ®Google Scholar
• W.H. Organization. Global hepatitis report, 2017. 2017.
   Google Scholar
• Yang YM, Kim SY, Seki E, Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin liver Dis, 39 (2019) 26–42.
   PubMed Web of Science ®Google Scholar
• Qin -J-J, Nag S, Wang W, Zhou J, Zhang W-D, Wang H, Zhang R. NFAT as cancer target: mission possible? Biochim Biophys Acta. 2014;1846(2):297–311. doi:10.1016/j.bbcan.2014.07.009.
   PubMed Web of Science ®Google Scholar
• Serrano-Perez MC, Fernandez M, Neria F, Berjon-Otero M, Doncel-Perez E, Cano E, Tranque P. NFAT transcription factors regulate survival, proliferation, migration, and differentiation of neural precursor cells. Glia. 2015;63(6):987–1004. doi:10.1002/glia.22797.
   PubMed Web of Science ®Google Scholar
• Pan MG, Xiong Y, Chen F. NFAT gene family in inflammation and cancer. Curr Mol Med. 2013;13(4):543–554. doi:10.2174/1566524011313040007.
   PubMed Web of Science ®Google Scholar
• Glud SZ, Sorensen AB, Andrulis M, Wang B, Kondo E, Jessen R, Krenacs L, Stelkovics E, Wabl M, Serfling E, et al. A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood. 2005;106(10):3546–3552. doi:10.1182/blood-2005-02-0493.
   PubMed Web of Science ®Google Scholar
• Lee H, Chouinard L, Bonin M, Michel RN. NFATc3 deficiency may contribute to the development of mammary gland adenocarcinoma in aging female mice. Mol Carcinog. 2005;44(3):219–222. doi:10.1002/mc.20136.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kieu C, Martin CE, Han J, Chen W, Kim JS, Kang MK, Kim RH, Park N-H, Kim Y, et al. NFATc3 plays an oncogenic role in oral/oropharyngeal squamous cell carcinomas by promoting cancer stemness via expression of OCT4. Oncotarget. 2019;10(23):2306–2319. doi:10.18632/oncotarget.26774.
   PubMedGoogle Scholar
• Lee SH, Rigas NK, Lee CR, Bang A, Srikanth S, Gwack Y, Kang MK, Kim RH, Park NH, Shin KH. Orai1 promotes tumor progression by enhancing cancer stemness via NFAT signaling in oral/oropharyngeal squamous cell carcinoma. Oncotarget. 2016 Jul 12;7(28):43239–43255. doi:10.18632/oncotarget.9755
   Google Scholar
• Lin F-C, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):369–376. doi:10.1016/j.cytogfr.2014.07.015.
   PubMed Web of Science ®Google Scholar
• Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2000;118(2):S83–103. doi:10.1016/S0016-5085(00)70008-4.
   PubMed Web of Science ®Google Scholar
• Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21(3):421–427. doi:10.1200/JCO.2003.10.103.
   PubMed Web of Science ®Google Scholar
• Zanoni I, Granucci F, Broggi A. Interferon (IFN)-lambda takes the helm: immunomodulatory roles of type III IFNs. Front Immunol. 2017;8:1661.
   PubMed Web of Science ®Google Scholar
• Tian S, Hui X, Fan Z, Li Q, Zhang J, Yang X, Ma X, Huang B, Chen D, Chen H. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1. FASEB j.. 2014;28(8):3528–3539. doi:10.1096/fj.14-250704.
   PubMed Web of Science ®Google Scholar
• Bao M, Wang Y, Liu Y, Shi P, Lu H, Sha W, Weng L, Hanabuchi S, Qin J, Plumas J, et al. NFATC3 promotes IRF7 transcriptional activity in plasmacy--toid dendritic cells. J Exp Med. 2016;213(11):2383–2398. doi:10.1084/jem.20160438.
   PubMed Web of Science ®Google Scholar
• Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680–692. doi:10.1016/j.immuni.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Koch A, Jeschke J, Van Criekinge W, van Engeland M, De Meyer T. MEXPRESS update. Nucleic Acids Res. 2019 2019;47(W1):W561–W565. doi:10.1093/nar/gkz445.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095
   Google Scholar
• Zhou W, Ma Y, Zhang J, Hu J, Zhang M, Wang Y, Li Y, Wu L, Pan Y, Zhang Y, et al. Predictive model for inflammation grades of chronic hepatitis B: large-scale analysis of clinical parameters and gene expressions. Liver Int. 2017;37:1632–1641.
   PubMed Web of Science ®Google Scholar
• Fekete JT, Ősz Á, Pete I, Nagy GR, Vereczkey I, Győrffy B. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. Gynecol Oncol. 2020;156:654–661.
   PubMed Web of Science ®Google Scholar
• Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997;41:1715–1720.
   PubMed Web of Science ®Google Scholar
• Yan Y, Allweiss L, Yang D, Kang J, Wang J, Qian X, Zhang T, Liu H, Wang L, Liu S, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection. Emerging Microbes Infect. 2019;8:879–894.
   PubMed Web of Science ®Google Scholar
• Cao L, Liu S, Li Y, Yang G, Luo Y, Li S, Du H, Zhao Y, Wang D, Chen J, et al. The nuclear matrix protein SAFA surveils viral RNA and facilitates immunity by activating antiviral enhancers and super-enhancers. Cell Host Microbe. 2019;26(3):369–384.e368. doi:10.1016/j.chom.2019.08.010.
   PubMed Web of Science ®Google Scholar
• Qi Z, Li G, Hu H, Yang C, Zhang X, Leng Q, Xie Y, Yu D, Zhang X, Gao Y, et al. Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice. J Virol. 2014;88(14):8045–8056. doi:10.1128/JVI.01024-14.
   PubMed Web of Science ®Google Scholar
• Fan Y, Mao R, Yu Y, Liu S, Shi Z, Cheng J, Zhang H, An L, Zhao Y, Xu X, et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med. 2014;211(2):313–328. doi:10.1084/jem.20122844.
   PubMed Web of Science ®Google Scholar
• You F, Wang P, Yang L, Yang G, Zhao YO, Qian F, Walker W, Sutton R, Montgomery R, Lin R, et al. ELF4 is critical for induction of type I interferon and the host antiviral response. Nat Immunol. 2013;14(12):1237–1246. doi:10.1038/ni.2756.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cheng J, Xu C, Liu S, Jiang S, Xu Q, Chen X, Zhuang H, Lu F. Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2012;32(3):420–428. doi:10.1111/j.1478-3231.2011.02696.x.
   PubMed Web of Science ®Google Scholar
• Huang L-R, Wu H-L, Chen P-J, Chen D-S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA. 2006;103(47):17862–17867. doi:10.1073/pnas.0608578103.
   PubMed Web of Science ®Google Scholar
• Jiang S, Yang Z, Li W, Li X, Wang Y, Zhang J, Xu C, Chen P-J, Hou J, McCrae MA, et al. Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PloS One. 2012;7(9):e40363. doi:10.1371/journal.pone.0040363.
   PubMed Web of Science ®Google Scholar
• Zevini A, Olagnier D, Hiscott J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 2017;38:194–205.
   PubMed Web of Science ®Google Scholar
• Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, Murakami S, Watanabe T, Iijima S, Sakurai Y, Watashi K, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity. 2015;42(1):123–132. doi:10.1016/j.immuni.2014.12.016.
   PubMed Web of Science ®Google Scholar
• Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, Robb N, Vreede F, Barclay W, Fodor E, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010;140(3):397–408. doi:10.1016/j.cell.2010.01.020.
   PubMed Web of Science ®Google Scholar
• Chow KT, Gale M, Loo Y-M. RIG-I and other RNA sensors in antiviral immunity. Annu Rev Immunol. 2018;36(1):667–694. doi:10.1146/annurev-immunol-042617-053309.
   PubMed Web of Science ®Google Scholar
• Perng Y-C, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nat Rev Microbiol. 2018;16(7):423–439. doi:10.1038/s41579-018-0020-5.
   PubMed Web of Science ®Google Scholar
• Reich NC. A death-promoting role for ISG54/IFIT2. J Interferon Cytokine Res. 2013;33(4):199–205. doi:10.1089/jir.2012.0159.
   PubMed Web of Science ®Google Scholar
• Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annual Review of Immunology. 1997;15(1):707–747. doi:10.1146/annurev.immunol.15.1.707.
   PubMed Web of Science ®Google Scholar
• Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IL, Sun H, Qin L, Qiu S, Lee JF, et al. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell. 2014;25(1):49–63. doi:10.1016/j.ccr.2013.11.011.
   PubMed Web of Science ®Google Scholar
• Liu Z, Dou C, Jia Y, Li Q, Zheng X, Yao Y, Liu Q, Song T. RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. Int J Oncol. 2015;46(4):1710–1720. doi:10.3892/ijo.2015.2853.
   PubMed Web of Science ®Google Scholar
• Bandi P, Pagliaccetti NE, Robek MD. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J Interferon Cytokine Res. 2010;30(3):123–134. doi:10.1089/jir.2009.0049.
   PubMed Web of Science ®Google Scholar
• Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α Transmembrane Signaling. J Biol Chem. 1995;270(27):15974–15978. doi:10.1074/jbc.270.27.15974.
   PubMed Web of Science ®Google Scholar
• Chow CW, Rincón M, Cavanagh J, Dickens M, Davis RJ. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science (New York, NY). 1997;278(5343):1638–1641. doi:10.1126/science.278.5343.1638.
   Google Scholar
• Müller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol. 2010;10(9):645–656. doi:10.1038/nri2818.
   PubMed Web of Science ®Google Scholar
• Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1):S84–s101. doi:10.1016/j.jhep.2016.02.021.
   PubMed Web of Science ®Google Scholar
• Macian F. NFAT proteins: key regulators of T-cell development and function, Nature reviews. Immunology. 2005;5(6):472–484. doi:10.1038/nri1632.
   PubMed Web of Science ®Google Scholar
• Zanoni I, Granucci F. Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs). Eur J Immunol. 2012;42:1924–1931.
   PubMed Web of Science ®Google Scholar
• Knolle PA. Hitting the right button: MAVS-mediated defense against HAV infection. Cell Res. 2017;27(1):7–8. doi:10.1038/cr.2016.139.
   PubMed Web of Science ®Google Scholar
• Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 2011;12:399–414.
   PubMed Web of Science ®Google Scholar
• Luo J, Sun L, Lin X, Liu G, Yu J, Parisiadou L, Xie C, Ding J, Cai H. A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons. Hum Mol Genet. 2014;23(24):6567–6574. doi:10.1093/hmg/ddu377.
   PubMed Web of Science ®Google Scholar